Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
10-year follow-up of early extra and routine MMR immunization
NL-OMON56402Completed
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Oct 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of measles, mumps, and rubella vaccine in measles, mumps and rubella (3 arms), sponsored by National Institute for Public Health and the Environment. Primary endpoints: Measles-specific serum IgG concentration and Measles virus neutralizing antibodies. Started Oct 2023; status: completed.
02
Drugs
measles, mumps, and rubella vaccine
03
Conditions
measlesmumpsrubella
Beyond the preview
Go deeper on NL-OMON56402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56402.